| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6582727 | EIRGEN | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
Aug, 2020
(3 years ago) | |
| US8906410 | EIRGEN | Oral dosage form of 25-hydroxyvitamin D |
Feb, 2027
(2 years from now) | |
| US10213442 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(2 years from now) | |
| US9943530 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(2 years from now) | |
| US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US8778373 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
| US9925147 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
| US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US11154509 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
| US8361488 | EIRGEN | Methods and compositions for controlled release oral dosage of a vitamin D compound |
Jul, 2028
(4 years from now) | |
| US8426391 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Aug, 2028
(4 years from now) | |
| US11801253 | EIRGEN | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
Sep, 2030
(6 years from now) | |
| US9861644 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
| US10357502 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
| US10300078 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
| US11253528 | EIRGEN | Stabilized modified release Vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
Rayaldee is owned by Eirgen.
Rayaldee contains Calcifediol.
Rayaldee has a total of 17 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rayaldee are:
- US6582727
Rayaldee was authorised for market use on 17 June, 2016.
Rayaldee is available in capsule, extended release;oral dosage forms.
Rayaldee can be used as treating secondary hyperparathyroidism in stage 3/4 chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversuppression, maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d, treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and tmax is increased compared to bolus iv injection and immediate-release, oral dosing, administration of 25-hydroxyvitamin d3 by controlled release, use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency, treatment of secondary hyperparathyroidism with sustained release 25-hydroxyvitamin d in chronic kidney disease patients receiving cyp3a inhibitors, use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease, treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d, use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4.
The generics of Rayaldee are possible to be released after 14 March, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d; Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RAYALDEE family patents
